drugset / Trial / NCT02427178

MNGIE Allogeneic Hematopoietic Stem Cell Transplant Safety Study

NCT02427178 ↗

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find out if a stem cell transplant is safe for patients with a very rare disease. The stem cell transplant is called AHSCT (for "allogeneic hematopoetic stem cell transplantation"). The rare disease is called MNGIE (for "Mitochondrial NeuroGastroIntestinal Encephalomyopathy"). Patients with MNGIE will be transplanted with stem cells from an individual who is human leukocyte antigen (HLA) 10/10 matched. The purpose of the transplant is the production of thymidine phosphorylase.

Timeline

Start
2015-03
Primary completion
2022-06
Completion
2023-06

Outcome

Outcome not reported

Stopped (Enrollment): “Poor enrollment”

Drugs

EvaluationDrugModalityDoseRoute
Subject Hematopoietic Allogeneic Stem Cells Cell therapy 2e+06 cells/kg Intravenous